Appili Therapeutics Inc. (APLIF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Appili Therapeutics Inc. (APLIF) trades at $0.01 with AI Score 51/100 (Grade B). Appili Therapeutics Inc. is a Canadian biopharmaceutical company focused on acquiring and developing novel medicines for infectious diseases. Market cap: $1.35M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for APLIF: APLIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates APLIF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
APLIF: the 1 perspectives are evenly split.
How is this calculated? →Appili Therapeutics Inc. (APLIF) Healthcare & Pipeline Overview
Appili Therapeutics Inc. is a Canadian biopharmaceutical company specializing in the acquisition and development of novel anti-infective drugs. With a focus on unmet needs in infectious diseases, Appili's portfolio includes treatments for anaerobic bacterial infections and cutaneous leishmaniasis, positioning them in a competitive biotechnology landscape.
What Is the Investment Thesis for APLIF?
Appili Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on unmet needs in infectious diseases offers potential for significant growth if its product candidates achieve regulatory approval and market adoption. Key value drivers include the successful clinical development and commercialization of ATI-1501, ATI-1801, and ATI-1701. The company's small market capitalization and limited financial resources introduce substantial risk, particularly regarding its ability to fund ongoing research and development activities. As of 2026-03-16, the company's financial performance and stock valuation are highly dependent on clinical trial outcomes and regulatory decisions.
Based on FMP financials and quantitative analysis
APLIF Key Highlights
- Appili Therapeutics operates with a small team of 7 employees, reflecting its early-stage development status.
- The company maintains a 100% gross margin, indicating efficient cost management in its operations.
- Appili Therapeutics has a negative free cash flow (FCF) of $-0.00B, highlighting its reliance on external funding for ongoing operations and research.
- The company's beta of -0.29 suggests a low correlation with the overall market, potentially offering some diversification benefits.
- Appili Therapeutics does not currently offer a dividend, typical for growth-focused biotechnology companies reinvesting earnings into research and development.
Who Are APLIF's Competitors?
APLIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical Inc. | $58.63 | -0.60% | $11.33B | 89 |
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| VRTX Vertex Pharmaceuticals Incorporated | $529.59 | +0.29% | 135B | 99 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are APLIF's Key Strengths?
- Focus on unmet needs in infectious diseases.
- Novel drug formulations and vaccine technologies.
- Experienced management team with expertise in drug development.
- Strong intellectual property protection for key products.
What Are APLIF's Weaknesses?
- Limited financial resources and reliance on external funding.
- Small size and lack of commercial infrastructure.
- High dependence on the success of a few key product candidates.
- OTC market listing may limit access to institutional investors.
What Could Drive APLIF Stock Higher?
- Clinical trial results for ATI-1501, ATI-1801, and ATI-1701, which could drive significant stock price movement.
- Regulatory approval decisions for any of Appili's product candidates, which would represent a major milestone.
- Strategic partnerships and collaborations with larger pharmaceutical companies, which could provide additional funding and expertise.
- Expansion into new markets and therapeutic areas, which could diversify the company's revenue streams.
- Acquisition of additional drug candidates to expand the portfolio, which could drive long-term growth.
What Are the Key Risks for APLIF?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or unexpected safety issues, which could delay or halt the development of their product candidates.
- Regulatory hurdles and lengthy approval processes, which could increase development costs and delay market entry.
- Competition from larger, more established pharmaceutical companies with greater resources.
- Limited financial resources and reliance on external funding, which could impact their ability to execute their business plan.
- OTC market listing may limit access to institutional investors and increase price volatility.
What Are the Growth Opportunities for APLIF?
- Expansion of ATI-1501 into new markets represents a significant growth opportunity. ATI-1501, a taste-masked reformulation of metronidazole, addresses a critical need for improved patient compliance in treating anaerobic bacterial infections. The global market for metronidazole is substantial, and Appili's improved formulation could capture a significant share, particularly among pediatric patients. Successful commercialization in North America and Europe could drive substantial revenue growth within the next 3-5 years.
- Development and commercialization of ATI-1801 for cutaneous leishmaniasis offers another growth avenue. Cutaneous leishmaniasis is a neglected tropical disease affecting millions worldwide. A novel topical formulation of paromomycin could provide a more effective and convenient treatment option. Successful clinical trials and regulatory approval could lead to significant market penetration, particularly in endemic regions. This growth opportunity has a potential timeline of 4-6 years, contingent on clinical trial outcomes.
- Advancement of ATI-1701, a live-attenuated vaccine for tularemia, presents a long-term growth opportunity. Tularemia is a rare but serious infectious disease with limited treatment options. A safe and effective vaccine could address a critical unmet need, particularly for high-risk populations. Development and regulatory approval of ATI-1701 could take 5-7 years, but the potential market is significant, particularly in regions where tularemia is endemic.
- Strategic partnerships and collaborations with larger pharmaceutical companies could accelerate Appili's growth. Collaborating with established players could provide access to additional funding, expertise, and distribution channels. These partnerships could facilitate the development and commercialization of Appili's product candidates, expanding its market reach and revenue potential. The timeline for securing such partnerships is variable but could yield near-term benefits.
- Acquisition of additional drug candidates and expansion of the anti-infective portfolio represents a continuous growth opportunity. Appili's expertise in infectious diseases positions it to identify and acquire promising drug candidates that address unmet needs. Expanding the portfolio could diversify the company's revenue streams and reduce its reliance on individual products. This strategy could lead to sustained growth over the long term, with a timeline dependent on the availability of suitable acquisition targets.
What Opportunities Does APLIF Have?
- Expansion into new markets and therapeutic areas.
- Strategic partnerships and collaborations with larger pharmaceutical companies.
- Acquisition of additional drug candidates to expand the portfolio.
- Increasing global demand for effective treatments for infectious diseases.
What Threats Does APLIF Face?
- Competition from larger, more established pharmaceutical companies.
- Regulatory hurdles and lengthy approval processes.
- Clinical trial failures and unexpected safety issues.
- Changes in government regulations and healthcare policies.
What Are APLIF's Competitive Advantages?
- Intellectual property protection (patents) on their drug formulations and vaccine technologies.
- Regulatory exclusivity for their approved products, which can prevent competitors from entering the market.
- Specialized expertise in the development and commercialization of anti-infective drugs.
- Established relationships with key opinion leaders and healthcare providers in the infectious disease field.
What Does APLIF Do?
Appili Therapeutics Inc., incorporated in 2015 and headquartered in Halifax, Canada, is a biopharmaceutical company dedicated to the acquisition and development of novel medicines targeting unmet needs in infectious diseases. The company's core focus lies in addressing critical gaps in the treatment of various infections through innovative pharmaceutical solutions. Appili's anti-infective portfolio features three primary assets: ATI-1501, a liquid oral taste-masked reformulation of metronidazole, designed to improve patient compliance in treating anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin intended for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine candidate aimed at providing protection against francisella tularensis, the causative agent of tularemia. Appili operates primarily within Canada, focusing on bringing innovative solutions to the Canadian healthcare market. The company's strategy involves identifying and acquiring promising drug candidates, reformulating existing drugs to improve their efficacy and patient experience, and developing novel vaccines to prevent infectious diseases.
What Products and Services Does APLIF Offer?
- Acquire novel medicines targeting infectious diseases.
- Develop new formulations of existing drugs to improve efficacy and patient compliance.
- Focus on unmet medical needs in the treatment of infectious diseases.
- Develop vaccines for the prevention of infectious diseases.
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Seek regulatory approval for their products in Canada and other markets.
- Commercialize and market their approved products to healthcare providers and patients.
- Focus on anti-infective portfolio including treatments for anaerobic bacterial infections, cutaneous leishmaniasis, and tularemia.
How Does APLIF Make Money?
- Acquire or in-license promising drug candidates in the field of infectious diseases.
- Develop and reformulate these drug candidates to improve their efficacy, safety, and patient compliance.
- Out-license or sell their developed products to pharmaceutical companies for commercialization, or commercialize themselves.
- Generate revenue through milestone payments, royalties on sales, and direct sales of their products.
What Industry Does APLIF Operate In?
Appili Therapeutics operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The global market for infectious disease treatments is substantial, driven by the emergence of new pathogens and the increasing prevalence of antibiotic resistance. Appili's focus on novel formulations and vaccines positions it to potentially capture a share of this market, but it faces competition from larger, more established pharmaceutical companies with greater resources.
Who Are APLIF's Key Customers?
- Healthcare providers (doctors, nurses, pharmacists) who prescribe and dispense their medications.
- Patients who receive their medications to treat infectious diseases.
- Pharmaceutical companies who license or acquire their drug candidates for commercialization.
- Government agencies and public health organizations who purchase their vaccines for disease prevention.
FY2026 estForward Outlook
Wall Street analysts project Appili Therapeutics Inc. revenue of about $245K for fiscal 2026, with EPS near $-0.05.
F-Score 3/9Financial Health
Appili Therapeutics Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE 20%Key Financial Metrics
Return on equity for Appili Therapeutics Inc. stands at 19.7%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -1.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -153.7%, the inverse of the P/E and a quick read on earnings relative to price.
Appili Therapeutics Inc. (APLIF) Valuation Context
Valued at $1.35M, APLIF is classified as a micro-cap stock. Relative to its peer group, APLIF's quantitative score of 51/100 is below the peer average of 88/100.
APLIF Revenue & Earnings Trend
In Q1 2026, APLIF generated $42K in top-line revenue, marking a sequential decrease of 63.4%. The company recorded a net loss of $1.0M, with diluted EPS of $-0.01. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.
Company Profile
Appili Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Halifax, CA. The company is led by CEO Donald D. Cilla Jr. Pharmd. APLIF has traded publicly since 2021.
APLIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's direction and potential upcoming developments.
- Community sentiment has shifted positively, with discussions highlighting recent clinical trial progresses.
- The market perceives Appili's innovative approach to infectious diseases as timely and relevant, boosting interest.
- Analysts have noted a growing interest in biotech stocks, particularly those focused on antiviral treatments, which could benefit Appili.
Bear Case
- Concerns linger about the timeline for product approvals, which may impact investor confidence in the short term.
- Recent social sentiment has shown skepticism regarding the company's ability to compete with larger pharmaceutical firms.
- There are reports of mixed reviews from recent clinical trial outcomes, leading to uncertainty in the community.
- Market volatility in the biotech sector raises questions about the sustainability of current investor interest in Appili.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $42,104 | -$1M | -$0.01 |
| Q4 2025 | $114,887 | -$948,727 | -$0.01 |
| Q3 2025 | $103,935 | -$989,065 | -$0.01 |
Based on FMP financials and quantitative analysis
APLIF Latest News
No recent news available for APLIF.
APLIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for APLIF.
Price Targets
Wall Street price target analysis for APLIF.
APLIF MoonshotScore
What does this score mean?
The MoonshotScore rates APLIF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
APLIF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Appili Therapeutics Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ, due to the potential for less transparency and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Wider bid-ask spreads and potential price volatility.
- Higher risk of fraud or manipulation.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and regulatory approvals.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Check for any regulatory actions or legal proceedings against the company.
- Company is properly registered and incorporated.
- Company has a physical address and contact information.
- Company has a website and actively communicates with investors.
- Company's management team has relevant experience in the industry.
- Company has a clear business plan and strategy.
Common Questions About APLIF (Healthcare)
What does Appili Therapeutics Inc. do?
Appili Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel anti-infective drugs. The company targets unmet needs in infectious diseases, reformulating existing drugs and developing new vaccines. Their portfolio includes ATI-1501, a taste-masked reformulation of metronidazole, ATI-1801 for cutaneous leishmaniasis, and ATI-1701, a vaccine for tularemia. Appili aims to improve patient outcomes and address critical gaps in the treatment of infectious diseases through innovative pharmaceutical solutions.
What do analysts say about APLIF stock?
As of 2026-03-16, formal analyst coverage of Appili Therapeutics (APLIF) is limited due to its OTC listing and small market capitalization. Therefore, there is no readily available analyst consensus on the stock. Potential investors should conduct their own thorough due diligence, considering the company's financial position, clinical trial progress, and regulatory outlook. The stock's valuation is highly dependent on the successful development and commercialization of its product candidates.
What are the main risks for APLIF?
Appili Therapeutics faces several key risks inherent to the biotechnology industry and its OTC listing. Clinical trial failures or unexpected safety issues with its drug candidates could significantly impact the company's prospects. Regulatory hurdles and lengthy approval processes pose additional challenges. Competition from larger pharmaceutical companies with greater resources is also a significant risk. Furthermore, the company's limited financial resources and OTC listing contribute to increased volatility and liquidity concerns for investors.
What are the key factors to evaluate for APLIF?
Appili Therapeutics Inc. (APLIF) holds an AI score of 51/100 (moderate). Not financial advice.
How frequently does APLIF data refresh on this page?
APLIF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven APLIF's recent stock price performance?
Appili Therapeutics Inc. (APLIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on unmet needs in infectious diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider APLIF overvalued or undervalued right now?
Valuing Appili Therapeutics Inc. (APLIF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying APLIF?
Before investing in Appili Therapeutics Inc. (APLIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- AI analysis pending for APLIF, which may provide additional insights.